N‐terminal B‐type natriuretic peptide (NT‐proBNP) is associated with disease severity in multiple myeloma

N‐terminal B‐type natriuretic peptide (NT‐proBNP) is associated with disease severity in... INTRODUCTIONMultiple myelomaMultiple myeloma (MM) is characterized by the neoplastic proliferation of a single plasma cell clone overproducing monoclonal immunoglobulins with multiple lesion sites accounting for approximately ten per cent of haematological malignancies. It is a heterogeneous disease; while some patients show rapid progression despite therapy, others remain asymptomatic for years. Multiple myeloma develops on the basis of a monoclonal gammopathy of uncertain significance to smouldering myeloma and finally leading to symptomatic multiple myeloma characterized by the occurrence of organ damage according to the CRAB criteria (hyperCalcaemia, Renal failure, Anaemia and Bone lesions). The therapy indications have just recently been revised and are now determined by the classical CRAB criteria and additional biomarkers of progression, as the free light chain (FLC) load, more than one bone lesion ≥5 mm diameter in magnetic resonance imaging and ≥60% clonal plasma cells in bone marrow, thereby including a small proportion of smouldering myeloma patients. Other known parameters associated with prognosis of MM patients are age, beta‐2‐microglobulin (B2M), serum calcium, haemoglobin, and albumin levels, kidney function and C‐reactive protein (CRP). The International Staging System (ISS) is a simple measure of disease severity based on B2M and albumin levels. In general, higher levels of B2M and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Investigation Wiley

N‐terminal B‐type natriuretic peptide (NT‐proBNP) is associated with disease severity in multiple myeloma

Loading next page...
 
/lp/wiley/n-terminal-b-type-natriuretic-peptide-nt-probnp-is-associated-with-s7UfODvYp3
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd
ISSN
0014-2972
eISSN
1365-2362
D.O.I.
10.1111/eci.12905
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONMultiple myelomaMultiple myeloma (MM) is characterized by the neoplastic proliferation of a single plasma cell clone overproducing monoclonal immunoglobulins with multiple lesion sites accounting for approximately ten per cent of haematological malignancies. It is a heterogeneous disease; while some patients show rapid progression despite therapy, others remain asymptomatic for years. Multiple myeloma develops on the basis of a monoclonal gammopathy of uncertain significance to smouldering myeloma and finally leading to symptomatic multiple myeloma characterized by the occurrence of organ damage according to the CRAB criteria (hyperCalcaemia, Renal failure, Anaemia and Bone lesions). The therapy indications have just recently been revised and are now determined by the classical CRAB criteria and additional biomarkers of progression, as the free light chain (FLC) load, more than one bone lesion ≥5 mm diameter in magnetic resonance imaging and ≥60% clonal plasma cells in bone marrow, thereby including a small proportion of smouldering myeloma patients. Other known parameters associated with prognosis of MM patients are age, beta‐2‐microglobulin (B2M), serum calcium, haemoglobin, and albumin levels, kidney function and C‐reactive protein (CRP). The International Staging System (ISS) is a simple measure of disease severity based on B2M and albumin levels. In general, higher levels of B2M and

Journal

European Journal of Clinical InvestigationWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial